A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2019
Price : $35 *
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Dova Pharmaceuticals
- 29 Sep 2019 According to a Swedish Orphan Biovitrum media release, the company is entering into a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer.
- 27 Jun 2019 According to an Dova Pharmaceuticals media release, top-line results from this study are expected in the first half of 2020.
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.